Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality 88% Improvement Relative Risk Progression 93% Progression (b) 92% primary Conv. Plasma  Avendaño-Solà et al.  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 81 patients in Spain (April - July 2020) Lower progression with convalescent plasma (p=0.013) c19early.org Avendaño-Solà et al., medRxiv, September 2020 Favors conv. plasma Favors control

Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial

Avendaño-Solà et al., medRxiv, doi:10.1101/2020.08.26.20182444, NCT04345523
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Early terminated RCT with 81 hospitalized patients, 38 treated with convalescent plasma, showing lower progression with treatment. NCT04345523 (history).
risk of death, 88.3% lower, RR 0.12, p = 0.12, treatment 0 of 38 (0.0%), control 4 of 43 (9.3%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29.
risk of progression, 93.0% lower, RR 0.07, p = 0.01, treatment 0 of 38 (0.0%), control 7 of 43 (16.3%), NNT 6.1, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29, progression to categories 5-7.
risk of progression, 91.9% lower, RR 0.08, p = 0.03, treatment 0 of 38 (0.0%), control 6 of 43 (14.0%), NNT 7.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 15, progression to categories 5-7, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Avendaño-Solà et al., 29 Sep 2020, Randomized Controlled Trial, Spain, peer-reviewed, 38 authors, study period 4 April, 2020 - 10 July, 2020, average treatment delay 8.0 days, trial NCT04345523 (history).
This PaperConv. PlasmaAll
Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
C Avendaño-Solà, A Ramos-Martínez, E Muñez-Rubio, B Ruiz-Antorán, R Malo De Molina, F Torres, A Fernández-Cruz, A Callejas-Díaz, J Calderón, C Payares-Herrera, I Salcedo, I Romera, J Lora-Tamayo, M Mancheño-Losa, M L Paciello, C Villegas, V Estrada, I Saez-Serrano, M L Porras-Leal, M C Jarilla-Fernández, J R Paño-Pardo JR, J A Moreno-Chulilla, I Arrieta-Aldea, A Bosch, M Belhassen-Garcia, O López-Villar, A Ramos-Garrido, L Blanco, M E Madrigal-Sánchez, E Contreras, E Muñiz-Díaz, J M Domingo-Morera, I Casas-Flecha, M Pérez-Olmeda, Javier Garcia-Pérez, J Alcamí, J L Bueno, R F Duarte
doi:10.1101/2020.08.26.20182444
Background: Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19 for which evidence from controlled clinical trials is lacking. Methods: We conducted a multi-center, randomized clinical trial in patients hospitalized for COVID-19. All patients received standard of care treatment, including off-label use of marketed medicines, and were randomized 1:1 to receive one dose (250-300 mL) of CP from donors with IgG anti-SARS-CoV-2. The primary endpoint was the proportion of patients in categories 5, 6 or 7 of the COVID-19 ordinal scale at day 15. Results: The trial was stopped after first interim analysis due to the fall in recruitment related to pandemic control. With 81 patients randomized, there were no patients progressing to mechanical ventilation or death among the 38 patients assigned to receive plasma (0%) versus 6 out of 43 patients (14%) progressing in control arm. Mortality rates were 0% vs 9.3% at days 15 and 29 for the active and control groups, respectively. No significant differences were found in secondary endpoints. At inclusion, patients had a median time of 8 days (IQR, 6-9) of symptoms and 49,4% of them were positive for anti-SARS-CoV-2 IgG antibodies. Conclusions : Convalescent plasma could be superior to standard of care in avoiding progression to mechanical ventilation or death in hospitalized patients with COVID-19. The strong dependence of results on a limited number of events in the control group prevents drawing firm conclusions about CP efficacy from this trial. (Funded by Instituto de Salud Carlos III; NCT04345523). .
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2007764
Califf, Hernandez, Landray, Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments.Observational Cacophony, Randomized Harmony, JAMA, doi:10.1001/jama.2020.13319
Cao, Wang, Wen, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, New England Journal of Medicine
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, New England Journal of Medicine
Chen, Xiong, Bao, Shi, Convalescent plasma as a potential therapy for COVID-19, Lancet Infect Dis
Gharbharan, Jordans, Geurtsvankessel, Convalescent Plasma for COVID-19. A randomized clinical trial, Medrxiv
Joyner, Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience, doi:10.1101/2020.08.12.20169359v1
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA. Published, doi:10.1001/jama.2020.10044
Mair-Jenkins, Saavedra-Campos, Baillie, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis
Petkova, Antman, Troxel, Pooling Data From Individual Clinical Trials in the COVID-19 Era, JAMA Published Online, doi:10.1001/jama.2020.13042
{ 'DOI': '10.1101/2020.08.26.20182444', 'URL': 'http://dx.doi.org/10.1101/2020.08.26.20182444', 'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Passive ' 'immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19 for which ' 'evidence from controlled clinical trials is ' 'lacking.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a ' 'multi-center, randomized clinical trial in patients hospitalized for COVID-19. All patients ' 'received standard of care treatment, including off-label use of marketed medicines, and were ' 'randomized 1:1 to receive one dose (250-300 mL) of CP from donors with IgG anti-SARS-CoV-2. ' 'The primary endpoint was the proportion of patients in categories 5, 6 or 7 of the COVID-19 ' 'ordinal scale at day ' '15.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The trial was ' 'stopped after first interim analysis due to the fall in recruitment related to pandemic ' 'control. With 81 patients randomized, there were no patients progressing to mechanical ' 'ventilation or death among the 38 patients assigned to receive plasma (0%) versus 6 out of 43 ' 'patients (14%) progressing in control arm. Mortality rates were 0% vs 9.3% at days 15 and 29 ' 'for the active and control groups, respectively. No significant differences were found in ' 'secondary endpoints. At inclusion, patients had a median time of 8 days (IQR, 6-9) of ' 'symptoms and 49,4% of them were positive for anti-SARS-CoV-2 IgG ' 'antibodies.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Convalescent ' 'plasma could be superior to standard of care in avoiding progression to mechanical ' 'ventilation or death in hospitalized patients with COVID-19. The strong dependence of results ' 'on a limited number of events in the control group prevents drawing firm conclusions about CP ' 'efficacy from this trial. (Funded by <jats:italic>Instituto de Salud Carlos ' 'III;</jats:italic><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ' 'ext-link-type="clintrialgov" ' 'xlink:href="NCT04345523">NCT04345523</jats:ext-link>).</jats:p></jats:sec>', 'accepted': {'date-parts': [[2020, 9, 29]]}, 'author': [ {'affiliation': [], 'family': 'Avendaño-Solà', 'given': 'C', 'sequence': 'first'}, {'affiliation': [], 'family': 'Ramos-Martínez', 'given': 'A', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Muñez-Rubio', 'given': 'E', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ruiz-Antorán', 'given': 'B', 'sequence': 'additional'}, {'affiliation': [], 'family': 'de Molina', 'given': 'R Malo', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Torres', 'given': 'F', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fernández-Cruz', 'given': 'A', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Callejas-Díaz', 'given': 'A', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Calderón', 'given': 'J', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Payares-Herrera', 'given': 'C', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Salcedo', 'given': 'I', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Romera', 'given': 'I', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Lora-Tamayo', 'given': 'J', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mancheño-Losa', 'given': 'M', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Paciello', 'given': 'ML', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Villegas', 'given': 'C', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Estrada', 'given': 'V', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Saez-Serrano', 'given': 'I', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Porras-Leal', 'given': 'ML', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Jarilla-Fernández', 'given': 'MC', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Paño-Pardo', 'given': 'JR', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Moreno-Chulilla', 'given': 'JA', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Arrieta-Aldea', 'given': 'I', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bosch', 'given': 'A', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Belhassen-Garcia', 'given': 'M', 'sequence': 'additional'}, {'affiliation': [], 'family': 'López-Villar', 'given': 'O', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ramos-Garrido', 'given': 'A', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Blanco', 'given': 'L', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Madrigal-Sánchez', 'given': 'ME', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Contreras', 'given': 'E', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Muñiz-Díaz', 'given': 'E', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Domingo-Morera', 'given': 'JM', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Casas-Flecha', 'given': 'I', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Pérez-Olmeda', 'given': 'M', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Garcia-Pérez', 'given': 'Javier', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Alcamí', 'given': 'J', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bueno', 'given': 'JL', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Duarte', 'given': 'RF', 'sequence': 'additional'}, {'affiliation': [], 'name': 'for the ConPlas-19 Study Group', 'sequence': 'additional'}], 'container-title': [], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 9, 1]], 'date-time': '2020-09-01T15:00:34Z', 'timestamp': 1598972434000}, 'deposited': { 'date-parts': [[2021, 2, 17]], 'date-time': '2021-02-17T22:11:15Z', 'timestamp': 1613599875000}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'indexed': {'date-parts': [[2024, 1, 25]], 'date-time': '2024-01-25T05:24:26Z', 'timestamp': 1706160266511}, 'institution': [{'name': 'medRxiv'}], 'is-referenced-by-count': 45, 'issued': {'date-parts': [[2020, 9, 1]]}, 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.08.26.20182444', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '246', 'original-title': [], 'posted': {'date-parts': [[2020, 9, 1]]}, 'prefix': '10.1101', 'published': {'date-parts': [[2020, 9, 1]]}, 'publisher': 'Cold Spring Harbor Laboratory', 'reference': [ { 'DOI': '10.1093/infdis/jiu396', 'doi-asserted-by': 'publisher', 'key': '2021021307351449000_2020.08.26.20182444v3.1'}, { 'DOI': '10.1056/NEJMoa2001282', 'article-title': 'A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe ' 'Covid-19', 'doi-asserted-by': 'crossref', 'first-page': '1787', 'journal-title': 'New England Journal of Medicine', 'key': '2021021307351449000_2020.08.26.20182444v3.2', 'volume': '382', 'year': '2020'}, { 'key': '2021021307351449000_2020.08.26.20182444v3.3', 'unstructured': 'Cavalcanti AB , Zampieri FG , Rosa RG , et al. Hydroxychloroquine with ' 'or without Azithromycin in Mild-to-Moderate Covid-19. New England ' 'Journal of Medicine 2020; published on July 23, 2020.'}, { 'DOI': '10.1056/NEJMoa2007764', 'doi-asserted-by': 'publisher', 'key': '2021021307351449000_2020.08.26.20182444v3.4'}, { 'key': '2021021307351449000_2020.08.26.20182444v3.5', 'unstructured': 'RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients ' 'with Covid-19. New England Journal of Medicine 2020; published on July ' '17,2020.'}, { 'DOI': '10.1001/jama.2020.10044', 'doi-asserted-by': 'publisher', 'key': '2021021307351449000_2020.08.26.20182444v3.6'}, { 'key': '2021021307351449000_2020.08.26.20182444v3.7', 'unstructured': 'Gharbharan A , Jordans C , GeurtsvanKessel C , et al. Convalescent ' 'Plasma for COVID-19. A randomized clinical trial. Medrxiv 2020: ' '2020.07.01.2013985 7v1.'}, { 'DOI': '10.1016/s1473-3099(20)30141-9', 'doi-asserted-by': 'publisher', 'key': '2021021307351449000_2020.08.26.20182444v3.8'}, { 'DOI': '10.1001/jama.2020.13319', 'doi-asserted-by': 'publisher', 'key': '2021021307351449000_2020.08.26.20182444v3.9'}, { 'key': '2021021307351449000_2020.08.26.20182444v3.10', 'unstructured': 'European Commission. An EU programme of COVID-19 convalescent plasma ' 'collection and transfusion. Guidance on collection, testing, processing, ' 'storage, distribution and monitored use. Version 1.0 April 4 2020. Most ' 'updated version accessible at ' 'https://ec.europa.eu/health/blood_tissues_organs/covid-19_en.'}, { 'key': '2021021307351449000_2020.08.26.20182444v3.11', 'unstructured': 'Center for Bio logics Evaluation and Research. Investigational COVID-19 ' 'Convalescent Plasma.Updated May 1, 2020. ' 'http://https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma. ' 'Accessed August 22.'}, { 'key': '2021021307351449000_2020.08.26.20182444v3.12', 'unstructured': 'Joyner MJ Effect of Convalescent Plasma on Mortality among Hospitalized ' 'Patients with COVID-19: Initial Three-Month Experience. ' 'https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1.'}, { 'DOI': '10.1001/jama.2020.13042', 'doi-asserted-by': 'publisher', 'key': '2021021307351449000_2020.08.26.20182444v3.13'}], 'reference-count': 13, 'references-count': 13, 'relation': {}, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.08.26.20182444'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'subtype': 'preprint', 'title': 'Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial', 'type': 'posted-content'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit